Ignite Creation Date:
2024-06-16 @ 11:52 AM
Last Modification Date:
2024-10-26 @ 3:31 PM
Study NCT ID:
NCT06453057
Status:
RECRUITING
Last Update Posted:
2024-06-11
First Post:
2024-06-07
Brief Title:
Autologous Tumor-Infiltrating Lymphocyte GT307 for Treatment of Patients With Solid Tumours
Sponsor:
Grit Biotechnology
Organization:
Grit Biotechnology
Study Overview
Official Title:
A Single-arm Clinical Study of Autologous Tumor-Infiltrating Lymphocyte GT307 for Treatment of Patients With Solid Tumours
Status:
RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is a single arm open design aimed at evaluating the safety and tolerability of Autologous Tumor-Infiltrating Lymphocyte GT307 for treatment of patients with solid tumourswhile evaluating pharmacokinetic characteristics and efficacy assessment to determine the optimal biological dose OBD
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None